Rakesh Jain - Tekla World Independent Trustee
THW Fund | USD 13.35 0.02 0.15% |
Dr. Rakesh K. Jain, Ph.D., serves as an Independent Trustee of the Tekla World Healthcare Fund. Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain cofounded XTuit Pharmaceuticals, Inc. in 2011, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institutes Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences.
Age | 69 |
Tenure | 9 years |
Phone | 617 772 8500 |
Web | https://www.teklacap.com/thw.html |
Tekla World Management Performance (%)
Similar Money Managers
Showing other executives | One Year Return | ||
Christopher Flynn | Royce Value Closed | N/A | |
Harriett Taggart | Eaton Vance Tax | 71 | |
William Cunningham | John Hancock Financial | 76 | |
Albert Laskaj | Cohen And Steers | 43 | |
Charles Bardelis | John Hancock Financial | 79 | |
Lucinda Stebbins | Tekla Healthcare Opportunities | 73 | |
Helen Peters | Eaton Vance Tax | 73 | |
Cynthia Frost | Eaton Vance Tax | 60 | |
Gregory Russo | John Hancock Financial | 71 | |
Mark Fetting | Eaton Vance Tax | 67 | |
Deborah Jackson | John Hancock Financial | 68 | |
Dr MS | Tekla Healthcare Investors | 71 | |
Lucinda Stebbins | Tekla Healthcare Investors | 73 | |
Warren Thomson | John Hancock Financial | 64 | |
Peter Burgess | John Hancock Financial | 78 | |
William Reardon | Tekla Life Sciences | 74 | |
Susan Sutherland | Eaton Vance Tax | 64 | |
Christopher MBA | Tekla Healthcare Investors | N/A | |
Lisa Phelan | Cohen And Steers | 51 | |
Lauren CFA | Royce Value Closed | N/A | |
Lucinda Stebbins | Tekla Life Sciences | 73 |
Tekla World Healthcare Leadership Team
Elected by the shareholders, the Tekla World's board of directors comprises two types of representatives: Tekla World inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla World's management team and ensure that shareholders' interests are well served. Tekla World's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla World's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Kent, Independent Trustee | ||
William Reardon, Independent Trustee | ||
Elizabeth Nabel, Independent Trustee | ||
Oleg Pohotsky, Independent Chairman of Board of Trustees | ||
Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
Lucinda Stebbins, Independent Trustee | ||
Jeffrey Bailey, Independent Trustee | ||
Daniel Omstead, President Trustee | ||
Rakesh Jain, Independent Trustee |
Tekla Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right fund is not an easy task. Is Tekla World a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Shares Outstanding | 37.49 M | ||||
Shares Owned By Institutions | 11.77 % | ||||
Number Of Shares Shorted | 157.29 K | ||||
Price To Earning | 12.08 X | ||||
Short Ratio | 1.43 X | ||||
Earnings Per Share | 1.16 X | ||||
Beta | 1.03 | ||||
Market Capitalization | 600.4 M | ||||
Annual Yield | 0.01 % | ||||
Year To Date Return | 17.88 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Tekla Fund
Tekla World financial ratios help investors to determine whether Tekla Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tekla with respect to the benefits of owning Tekla World security.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |